327 related articles for article (PubMed ID: 37326394)
1. P53/MDM2 Complex-Based Targeted Strategies in Colon Adenocarcinoma.
Niotis A; Tsiambas E; Dimitroulis D; Sarlanis H; Falidas E; Kavantzas N; Constantinides CA
Acta Med Acad; 2023 Apr; 52(1):24-29. PubMed ID: 37326394
[TBL] [Abstract][Full Text] [Related]
2. Deregulation of p53-MDM2 auto-regulatory pathway in breast carcinoma.
Baliou E; Nonni A; Keramopoulos D; Ragos V; Tsiambas E; Patsouris E; Pavlakis K
J BUON; 2016; 21(5):1099-1103. PubMed ID: 27837610
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.
Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; Domingos S; Pinto M; Inga A; Cidade H; Saraiva L
Life Sci; 2015 Dec; 142():60-5. PubMed ID: 26475964
[TBL] [Abstract][Full Text] [Related]
4. Comparative Expression Analysis of
Niotis A; Dimitroulis D; Spyropoulou D; Tsiambas E; Sarlanis H; Davris D; Falidas E; Kavantzas N; Peschos D; Manaios L; Konstantinidis KC
Cancer Diagn Progn; 2024; 4(2):129-134. PubMed ID: 38434910
[TBL] [Abstract][Full Text] [Related]
5. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
[TBL] [Abstract][Full Text] [Related]
7. Prolyl hydroxylase 3 stabilizes the p53 tumor suppressor by inhibiting the p53-MDM2 interaction in a hydroxylase-independent manner.
Xu Y; Gao Q; Xue Y; Li X; Xu L; Li C; Qin Y; Fang J
J Biol Chem; 2019 Jun; 294(25):9949-9958. PubMed ID: 31092600
[TBL] [Abstract][Full Text] [Related]
8. L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells.
Ayroldi E; Petrillo MG; Bastianelli A; Marchetti MC; Ronchetti S; Nocentini G; Ricciotti L; Cannarile L; Riccardi C
Cell Death Differ; 2015 Jan; 22(1):118-30. PubMed ID: 25168242
[TBL] [Abstract][Full Text] [Related]
9. Identification of XBP1-u as a novel regulator of the MDM2/p53 axis using an shRNA library.
Huang C; Wu S; Ji H; Yan X; Xie Y; Murai S; Zhao H; Miyagishi M; Kasim V
Sci Adv; 2017 Oct; 3(10):e1701383. PubMed ID: 29057323
[TBL] [Abstract][Full Text] [Related]
10. mdm2 oncogene in laryngeal squamous cell carcinoma.
Mastronikolis N; Ragos V; Fotiades P; Papanikolaou V; Kyrodimos E; Chrysovergis A; Mastronikolis S; Tsiambas E
J BUON; 2020; 25(2):594-596. PubMed ID: 32521839
[TBL] [Abstract][Full Text] [Related]
11. Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.
Jung CR; Lim JH; Choi Y; Kim DG; Kang KJ; Noh SM; Im DS
J Clin Invest; 2010 Dec; 120(12):4493-506. PubMed ID: 21060154
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
13. P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: a case control study.
Ren YW; Yin ZH; Wan Y; Guan P; Wu W; Li XL; Zhou BS
Asian Pac J Cancer Prev; 2013; 14(9):5415-20. PubMed ID: 24175836
[TBL] [Abstract][Full Text] [Related]
14. Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53.
Riscal R; Schrepfer E; Arena G; Cissé MY; Bellvert F; Heuillet M; Rambow F; Bonneil E; Sabourdy F; Vincent C; Ait-Arsa I; Levade T; Thibaut P; Marine JC; Portais JC; Sarry JE; Le Cam L; Linares LK
Mol Cell; 2016 Jun; 62(6):890-902. PubMed ID: 27264869
[TBL] [Abstract][Full Text] [Related]
15. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
16. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
[TBL] [Abstract][Full Text] [Related]
17. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
18. Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase.
Giono LE; Resnick-Silverman L; Carvajal LA; St Clair S; Manfredi JJ
Oncogene; 2017 Dec; 36(49):6762-6773. PubMed ID: 28806397
[TBL] [Abstract][Full Text] [Related]
19. The RASSF6 tumor suppressor protein regulates apoptosis and the cell cycle via MDM2 protein and p53 protein.
Iwasa H; Kudo T; Maimaiti S; Ikeda M; Maruyama J; Nakagawa K; Hata Y
J Biol Chem; 2013 Oct; 288(42):30320-30329. PubMed ID: 24003224
[TBL] [Abstract][Full Text] [Related]
20. miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2.
Jansson MD; Damas ND; Lees M; Jacobsen A; Lund AH
Oncogene; 2015 Apr; 34(15):1908-18. PubMed ID: 24882579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
